{
  "extraction_metadata": {
    "timestamp": "2025-10-02T14:53:37.689933",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "temperature": 0.1
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "Outcomes": "overall survival, progression-free survival, partial response, complete remission, time to deterioration, time to progression of the tumor, intraoperative complications, mortality, morbidity",
      "ChunksUsed": 8,
      "ContextTokens": 2059
    },
    "BE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "BE",
      "Outcomes": "partial response, survival, objective response, liver failure, pain, fever, serious complications, portal vein thrombosis, recurrence, adverse events (general)",
      "ChunksUsed": 8,
      "ContextTokens": 1885
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "Outcomes": "overall survival, progression-free survival, partial response, complete remission, intraoperative complications, mortality, morbidity, disease progression, time to deterioration, time to progression of the tumor",
      "ChunksUsed": 8,
      "ContextTokens": 2059
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "Outcomes": "5-year survival, prognosis based on diameter of largest tumour, prognosis based on number of tumours in the liver, presence of extrahepatic tumour, microinvasion, long-term survival, perioperative mortality, morbidity, leukaemia, postoperative softening, gallbladder abscess, risk of recurrence, complications, performance status, tumour stage at diagnosis, severity of underlying liver disease",
      "ChunksUsed": 8,
      "ContextTokens": 1421
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "Outcomes": "survival, median survival (by HCC stage), therapeutic efficacy, recurrence detection, long-term treatment-related complications",
      "ChunksUsed": 8,
      "ContextTokens": 1633
    },
    "EU": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EU",
      "Outcomes": "adverse events",
      "ChunksUsed": 8,
      "ContextTokens": 2242
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "Outcomes": "time-to-progression, toxicity, overall survival, response rates, adverse events, diarrhoea, fatigue, nausea, neutropenia, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L, adverse events (CTCAE v5.0), RECIST criteria",
      "ChunksUsed": 8,
      "ContextTokens": 2444
    },
    "IT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "IT",
      "Outcomes": "improved survival, response rates, adverse events, diarrhoea, fatigue, nausea, neutropenia, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L",
      "ChunksUsed": 8,
      "ContextTokens": 1960
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "Outcomes": "overall survival, progression-free survivorship, response rate, tumour response rate, adverse events, adverse events (Grade â‰¥ 3), quality of life, overall quality of life (measured with a validated and reliable instrument), local tumour control, success rate (downstaging/bridging), complications",
      "ChunksUsed": 8,
      "ContextTokens": 2017
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "Outcomes": "response rates (RECIST criteria), response rates (mRECIST), response rates (RECIS systems), response assessment (multiphase computed tomography with contrast), response assessment (magnetic resonance imaging with contrast), perioperative mortality, adverse events (general), microscopic detection of cancer (histological and prognostic parameters), immunohistochemical confirmation of hepatocytic origin, genetic diagnosis (identification of subtypes), completeness of ablation (multiphase computed tomography with contrast), follow-up examination after ablation (magnetic resonance imaging), follow-up examination after ablation (multiphase computed tomography)",
      "ChunksUsed": 8,
      "ContextTokens": 1798
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "Outcomes": "EORTC QLQ-30, FACT-G, EORTC QLQ-HCC18, FACT-Hep, survival, quality of life",
      "ChunksUsed": 8,
      "ContextTokens": 1459
    }
  }
}